a middle-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56
📊
Treatment Reviews
See user reviews and ratings for a middle-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56
🔬
Mega-Study
See real-world data analysis for a middle-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56
📚
Meta-Analysis
See a meta-analysis of all available research
🔍
Clinical Trials
See clinical trials related to a middle-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56